Dr Anna Olsson-Brown

Anna Olsson-Brown is a consultant in medical oncology. She specialises in the systemic treatment of skin cancers; immunotherapeutic toxicities, early phase/translational clinical trials and acute oncology. She is the clinical director for Clinical Cancer Services at Sussex Cancer Centre, honorary consultant at UCLH serving as an expert oncologist with the immunotherapy-neurotoxicity service, honorary consultant at LHCH within their cardio-oncology service and an honorary senior lecturer at the University of Liverpool.

She has a background in clinical pharmacology and an interest in acute oncology and supportive care for cancer patients particularly with regards to toxicity of cancer therapies. She was an MRC research fellow completing her PhD investigating the mechanisms of immunotherapy toxicity and has subsequently published extensively in the area.

She established and led a pan-tumour, pan-regional immunotherapy toxicity service supporting inpatients and outpatients with immunotherapy toxicities and providing a clinical-research interface supporting a number of translational trials prior to her move to Sussex and now leads the service there.

She was the immunotherapy toxicity work stream lead for the NIHR Oncology Translational Research Committee (O-TRC) and has multiple UK research collaborations. She is also a trustee and board member of UKASCC. She is a founding member and current CEO of the National Immunotherapy Clinical Network (IOCN) and sits on the UK SACT Board within this role. She is also the Toxicity Workstream Co-lead within the UK Acute Oncology Society. She is a current oncology representative of the Symposium Committee at the Royal College of Physicians of Edinburgh, representative on the Association of Cancer Physicians and RCPE new consultant committees and the NIHR-BHF Cardio-oncology working group.